Novo Nordisk expands production in the US
Novo Nordisk is planning a US$100m expansion of its insulin manufacturing plant in Clayton, North Carolina. The move will create around 200 new jobs, bringing the total to 600 once the facility is fully operational.
Novo Nordisk is planning a US$100m expansion of its insulin manufacturing plant in Clayton, North Carolina. The move will create around 200 new jobs, bringing the total to 600 once the facility is fully operational.
The first phase of the plant expansion, scheduled for completion in 2006, will allow Novo Nordisk to more than double its insulin filling capacity in the US. The second phase will include assembly and packaging facilities for Novo Nordisk's prefilled insulin delivery device FlexPen as well as administration and storage space, with expected completion in 2007.
Currently, the Clayton plant handles the formulation, filling and packaging of Novo Nordisk insulin preparations. The site is a high-volume, high-speed integrated facility that supplies both the US and other worldwide markets. A $12m addition was recently completed.
'The new facility supports our business by aligning the capacity of our Clayton plant with the increasing demand for Novo Nordisk's insulin products in the US,' said Lars Rebien Sorensen, president and ceo of Novo Nordisk.
The company has increased its US market share considerably in recent years, driven by the insulin analogues NovoLog and NovoLog Mix, and now holds slightly more than one third of the US insulin market and close to 20% of the analogue market.